



General Meeting Results

Melbourne, Australia, 28 November 2024 – InhaleRx Ltd (ASX: IRX), (**‘IRX’ or ‘the Company’**) an Australian healthcare company developing unique inhaled drug-device products to address unmet medical needs in the pain management and mental health sectors, advises a General Meeting was held today, 28 November 2024, commencing at 4pm AEDT.

All resolutions were put to a poll. In accordance with Listing Rule 3.13.2 and section 251AA of the Corporations Act 2001 (Cth), details of the resolutions, proxies received in respect of each resolution and poll results are set out in the attached summary.

The Board thanks shareholders for their support and looks forward to providing further updates as it executes its strategy.

Authorised by the Board of Directors.

For further information:

www.inhalerx.com.au

James Barrie, Company Secretary
Phone +61 3 8678 4091

About InhaleRx Limited (ASX: IRX) – www.inhalerx.com.au

InhaleRx Limited is an Australian healthcare company which is developing unique medicinal drug-device products to address unmet medical needs in pain management and mental health sectors.

The overarching goal is to pursue U.S. FDA approval and registration using rapid and cost-effective regulatory pathways, such as 505(b)(2).

There is a significant economic opportunity for IRX and the Company’s shareholders. The first medical indications under investigation are Breakthrough Cancer Pain (**‘BTcP’**) and Panic Disorder (**‘PD’**), both of which currently have limited safe and effective treatment options.

IRX holds an innovation patent and provisional patents for the nominated indications and the Company plans to continue to strengthen this position.



In accordance with section 251AA of the Corporations Act 2001, the following information is provided in relation to the resolutions put to members at the meeting, which were **decided on a Poll**.

	Resolution	Proxy Votes						Poll			Result
		For	Against	Open	Exclusions	Abstain	Total	For	Against	Abstain	Carried / Not Carried
Resolution 1	ISSUE OF SHARES TO A DIRECTOR IN LIEU OF DIRECTOR FEES - SEAN WILLIAMS	19,026,119	3,675,541	-	1,282,092	3,282,013	22,701,660	67,357,006	3,675,541	10,469,751	Carried
		83.81%	16.19%	0.00%				94.83%	5.17%		
Resolution 2	ISSUE OF SHARES TO A DIRECTOR IN LIEU OF DIRECTOR FEES - ANDREW SAICH	19,026,119	3,675,541	-	1,282,092	3,282,013	22,701,660	67,357,006	3,675,541	10,469,751	Carried
		83.81%	16.19%	0.00%				94.83%	5.17%		
Resolution 3	ISSUE OF SHARES TO A DIRECTOR IN LIEU OF DIRECTOR FEES - JAMES BARRIE	19,310,118	3,391,542	-	1,282,092	3,282,013	22,701,660	67,641,005	3,391,542	10,469,751	Carried
		85.06%	14.94%	0.00%				95.23%	4.77%		
Resolution 4	ISSUE OF SHARES TO A DIRECTOR IN LIEU OF DIRECTOR FEES - JOHN CROCK	19,026,119	3,675,541	-	1,282,092	3,282,013	22,701,660	67,357,006	3,675,541	10,469,751	Carried
		83.81%	16.19%	0.00%				94.83%	5.17%		
Resolution 5	RATIFICATION OF PRIOR ISSUE OF SHARES	22,572,131	3,411,542	-	1,282,092	-	25,983,673	29,759,869	3,411,542	-	Carried
		86.87%	13.13%	0.00%				89.72%	10.28%		
Resolution 6	RATIFICATION OF PRIOR ISSUE OF CONVERSION SHARES	25,113,673	20,000	200,000	1,282,092	650,000	25,333,673	25,313,673	20,000	650,000	Carried
		99.13%	0.08%	0.79%				99.92%	0.08%		
Resolution 7	APPROVAL TO ISSUE OF OPTIONS TO CLENDON UNDER THE FACILITY AGREEMENT	25,963,673	20,000	-	1,282,092	-	25,983,673	81,482,298	20,000	-	Carried
		99.92%	0.08%	0.00%				99.98%	0.02%		